Discussion: The B.1.351 variant is known worldwide for its immune escape property due to the mutations K417N, E484K and N501Y in the RBD of the spike region.
Optimization and Application of a Multiplex Digital PCR Assay for the Detection of SARS-CoV-2 Variants of Concern in Belgian Influent Wastewater.
Abstract: Key mutations were targeted in the different VOC strains, including SDelta69/70 deletion, N501Y, SDelta241 and SDelta157.
Introduction: Multiple methods have been developed targeting single-nucleotide polymorphisms (e.g., N501Y and E484K) or characteristic deletions (e.g., spike SDelta69/70 deletion and ORF1a Delta3675-3677) in the genome (often the spike domain) of the SARS-CoV-2 virus.
Result: 1.1.7 and N501Y primer set, the assays for P1 and B.1.617.2 VOC were found specific with the RT-qPCR method.
Result: Additionally, the N501Y primer set did not target the B.1.617.2.
Result: As discussed earlier, the N501Y primer set should yield in
Fractionation of sulfated galactan from the red alga Botryocladia occidentalis separates its anticoagulant and anti-SARS-CoV-2 properties.
PMID: 35337800
2022
The Journal of biological chemistry
Result: 5D), Alpha N501Y.
Result: 5F), and Gamma K417T/E484K/N501Y.
Result: Fractions Fr1-Fr4 showed strong binding affinity for the Alpha N501Y mutant.
Result: Heparin binding to the N501Y mutant lacked any interaction with Y501.
Result: In addition, through the competitive SPR assay (Table 4), it is also demonstrated that the native BoSG has stronger binding affinities for the N501Y-containing RBDs than for the single L452R mutant or wild type RBD.
Result: Molecular docking of BoSG-derived disaccharide constructs to N
Table: N501Y
E-Volve: understanding the impact of mutations in SARS-CoV-2 variants spike protein on antibodies and ACE2 affinity through patterns of chemical interactions at protein interfaces.
Introduction: As in cases of reinfection, by the non-synonymous convergent spike mutations N501Y, appearing in all of them, E484K occurring on the Gamma and in the Beta and K417T taking place in the Gamma variant.
Introduction: It presents the following mutations: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, and T1027I.
Introduction: One of those effects revealed by Nelson and collaborators is the increased affinity between the Receptor-Binding Domain ( PMID: 35345417
2022
The Lancet. Microbe
Discussion: The three mutations characterising the beta variant (K417N, E484K, and N501Y) are located at the receptor-binding domain, making the variant resistant to some potent neutralising antibodies.
AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.
Introduction: The beta variant bears genetic changes in the functional domain of the SARS-CoV-2 spike (S) protein including substitutions in the receptor-binding domain (RBD) (E484K, N501Y and K417N), four substitutions and a deletion in N-terminal domain (NTD) (L18F, D80A, D215G, L242H and R246I) and substitutions in S2 (D614G and A701V) regions.
Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2.
Introduction: Beta+R346K and Mu+K417N share the same haplotype with R346K, K417N, E484K and N501Y mutations in the receptor-binding domain (RBD) in the spike protein, as shown in Figure 2.
Introduction: In late September, the Alpha variant (B.1.1.7) harboring the N501Y mutation that conferred higher infectivity emerged in the UK and spread rapidly all over the world before vaccines became widely available in December.
Discussion: reported that neutralization efficacy was reduced for the Mu variant harboring R346K, E484K and N501Y in the PMID: 35367284
2022
Virus research
Table: N501Y
Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach.
PMID: 35370005
2022
Indian journal of medical microbiology
Table: N501Y
Discussion: D614G, T20N, D138Y, L18F, R190S, and P26S in the NTD and K417T, E484K and N501Y in the RBD region and H655Y within the furin cleavage site.
CRISPR-Cas13a cascade-based viral RNA assay for detecting SARS-CoV-2 and its mutations in clinical samples.
PMID: 35370361
2022
Sensors and actuators. B, Chemical
Result: 5, A), to test their capability of distinguishing the N501Y mutant from the wild type.
Result: Spike glycoprotein mutations, such as the N501Y mutation, are present in many SARS-CoV-2 variants.
Result: Then, we sought to determine if the Cas13C assay had the ability to discriminate N501Y mutations in the presence of varying proportions of wild type RNAs.
Result: We found that the Cas13C assay was able to discriminate the N501Y-mutated variant when it was
Figure: (A) Design of crRNA_S (1-5) for identifying N501Y mutations.
Figure: (C) The Cas13C assay can detect the mutant N501Y in wild SARA-CoV-2 samples.
Figure: Identify N501Y mutations of SARS-CoV-2 variants.
SARS_CoV_2 mutation literature information.
PMID: 
2022
Viruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT